Amber L Kokal, M.S. Psychologist - School Medicare: Not Enrolled in Medicare Practice Location: 16000 E High St, Middlefield, OH 44062 Phone: 440-632-0264 |
News Archive
Caliper Life Sciences, Inc., a leading provider of products and services for drug discovery research, today announced that it has entered into a definitive agreement to acquire privately-held Cambridge Research & Instrumentation, Inc. (CRi) for approximately $20.0 million, including net debt. CRi's patented preclinical and tissue-based multiplexed analysis systems will expand Caliper's life sciences tools portfolio, particularly as it bridges into clinical research, pathology and clinical market applications.
"The Obama administration has selected eight countries to serve as learning labs for a new global health strategy aimed in part at reducing maternal and child deaths and combatting preventable diseases," the Wall Street Journal reports. "The move is among the first steps in the administration's" roll-out of the Global Health Initiative and "comes amid mounting concerns about how much support President Barack Obama will win from Congress for a proposed 9% increase in global health spending for fiscal 2011," the newspaper reports.
Anacor Pharmaceuticals announced today that it has completed the enrollment of approximately 600 patients in the second of its two Phase 3 trials of tavaborole, a topical anti-fungal product candidate for the treatment of onychomycosis, a fungal infection of the nail and nail bed that affects approximately 35 million people in the United States.
"U.S. support for global health has had a major impact around the world, particularly our contributions to fighting malaria through the President's Malaria Initiative and the Global Fund to Fight AIDS, Tuberculosis, and Malaria," Rep. Ander Crenshaw (R-Fla.), co-chair of the Congressional Caucus on Malaria and Neglected Tropical Diseases, and Steve Davis, CEO of PATH, write in a Washington Times opinion piece.
Neoprobe Corporation, a diversified developer of innovative oncology surgical and diagnostic products, today announced that a multi-center Phase 3 study of Lymphoseek® has enrolled clinical subjects to achieve the minimum analysis goal of 196 lymph nodes, the study's primary accrual objective.
› Verified 8 days ago